Highlights of This Issue 4731

SPECIAL FEATURES

CCR Translations

4733 Prostate Cancer SubtyPINg BiomarKers and Outcome: Is Clarity EmERGing? Steven C. Smith and Scott A. Tomlins See related article, p. 4904

4737 Twisting and Ironing: Doxorubicin Cardiotoxicity by Mitochondrial DNA Damage Karin C. Nitiss and John L. Nitiss See related article, p. 4873

Molecular Pathways

4740 Molecular Pathways: Targeting RAC–p21-Activated Serine–Threonine Kinase Signaling in RAS-Driven Cancers Nicole M. Baker, Hoi Yee Chow, Jonathan Chernoff, and Channing J. Der

CANCER THERAPY: CLINICAL

4747 Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors Paul Haluska, Michael Menezee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, and Patricia LoRusso


4768 The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials A. Schwandt, P.J. Harris, S. Hunsberger, A. Deleporte, G.L. Smith, D. Vulih, B.D. Anderson, and S.P. Ivy

4776 Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors Diane A.J. van der Biessen, Herman Burger, Peter de Bruijn, Cor H.J. Lammers, Nicole Naus, Hannes Loferer, Erik A.C. Wiemer, Ron H.J. Mathijsen, and Maja J.A. de Jonge

PERSONALIZED MEDICINE AND IMAGING

4784 A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma Motonobu Saito, Kouya Shiraiishi, Kenji Matsumoto, Aaron J. Schetter, Hiroko Ogata-Kawata, Naoto Tsuchiya, Hideo Kunitoh, Hiroshi Nokihara, Shun-ichi Watanabe, Koji Taura, Kensuke Kumamoto, Seiichi Takenoshita, Jun Yokota, Curtis C. Harris, and Takashi Kohn

4794 Clinical Significance of EpCAM mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform Wei Guo, Xin-Rong Yang, Yun-Fan Sun, Min-Na Shen, Xiao-Lu Ma, Jiong Wu, Chun-Yan Zhang, Yan Zhou, Yang Xu, Bo Hu, Xin Zhang, Jian Zhou, and Jia Fan


Table of Contents

4827  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
Apostolia-Maria Tsimberidou, Sijin Wen, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Suqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Kenneth Aldape, Yang Ye, Razelle Kurzrock, and Donald Berry

4837  Systematically Defining Single-Gene Determinants of Response to Neoadjuvant Chemotherapy Reveals Specific Biomarkers
Agnieszka K. Witkiewicz, Uthra Balaji, and Erik S. Knudsen

CANCER THERAPY: PRECLINICAL

4849  PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo
Mohamed Rahmani, Mandy Mayo Aust, Elisa C. Benson, LaShanale Wallace, Jonathan Friedberg, and Steven Grant

4861  On-Target Effect of FK866, a Nicotinamide Phosphoribosyl Transferase Inhibitor, by Apoptosis-Mediated Death in Chronic Lymphocytic Leukemia Cells
Iris Gehrke, Eric D.J. Bouchard, Sara Beiggi, Armando G. Poepl, James B. Johnston, Spencer B. Gibson, and Versha Banerji

4873  Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity
Salim Khiati, Ilaria Dalla Rosa, Carole Sourbier, Xuefei Ma, V. Ashutosh Rao, Leonard M. Neckers, Hongliang Zhang, and Yves Pommier
See related commentary, p. 4737

4882  Demethylating Drugs as Novel Analgesics for Cancer Pain
Chi T. Viet, Dongmin Dang, Yi Ye, Kentaro Ono, Ronald R. Campbell, and Brian L. Schmidt

BIOLOGY OF HUMAN TUMORS

4894  Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation

4904  SPINK1 Protein Expression and Prostate Cancer Progression
Richard Flavin, Andreas Pettersson, Whitney K. Hendrickson, Michelangelo Fiorentino, Stephen Finn, Lauren Kunz, Gregory L. Judson, Rosina Lis, Dyane Bailey, Christopher Giaccone, Elizabeth Nuttall, Neil E. Martin, Edward Stack, Kathryn L. Penney, Jennifer R. Rider, Jennifer Sinnott, Christopher Sweeney, Howard D. Sesso, Katja Fall, Edward Giovannucci, Philip Kantoff, Meir Stampfer, Massimo Loda, and Lorelei A. Mucci
See related commentary, p. 4733

4912  Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to Smoking History
Anna Karlsson, Markus Ringnér, Martin Lauss, Johan Botling, Patrick Micke, Maria Planck, and Johan Staaf

4925  Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men
Francesca Khani, Juan Miguel Mosquera, Kyung Park, Mirjam Blattner, Catherine O’Reilly, Theresa Y. MacDonald, Zhongming Chen, Abhishek Srivastava, Ashutosh K. Tewari, Christopher E. Barbieri, Mark A. Rubin, and Brian D. Robinson

4935  Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer
Michael L. Nickerson, Garrett M. Dancik, Kate M. Im, Michael G. Edwards, Sevilay Turan, Joseph Brown, Christina Ruiz-Rodriguez, Charles Owens, James C. Costello, Guangwu Guo, Shirley X. Tsang, Yingrui Li, Quan Zhou, Zhiming Cai, Lee E. Moore, M. Scott Lucia, Michael Dean, and Dan Theodore

4949  T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness
Filipe Pinto, Neila Pertegá-Gomes, Márcia S. Pereira, José R. Vizcaíno, Pedro Monteiro, Rui M. Henrique, Fátima Baltazar, Raquel P. Andrade, and Rui M. Reis
Excess of Proximal Microsatellite-Stable Colorectal Cancer in African Americans from a Multiethnic Study

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Letter
Nima Sharifi and Richard J. Auchus

Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancer—Response
Christopher M. Hovens, Matthew K.H. Hong, and Niall M. Corcoran

Correction: Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries

The cover shows results from FISH analysis of prostate cancer cells with ERG rearrangement (top; loss of one green signal indicating translocation through deletion) and hemizygous PTEN deletion (bottom; loss of one red signal with preservation of green centromeric signals). For details, see the article by Khani and colleagues on page 4925 of this issue.
Clinical Cancer Research

20 (18)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/18

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.